Address: The Registry, Royal Mint Court, London EC3N 4QN, United Kingdom ,United Kingdom
Tel: +44 (0)20 7457 2018
Web: http://www.britishgenerics.co.uk/
The British Generic Manufacturers Association (BGMA) represents the interests of UK-based manufacturers and suppliers of generic medicines and promotes the development and understanding of the generic medicines industry in the United Kingdom.
The BGMA is made up of about 20 members of the generic manufacturing industry, who between them account for more than 85% of the UK generic market by volume. Generic medicines competition saves the NHS £7bn per annum.
The BGMA represent the views and interests of its members to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the Institutions of the European Union and the media.
The BGMA has the following aims and objectives:
Aims
x To ensure that the UK distribution mechanisms and NHS reimbursement scheme for community pharmacy is as attractive to Generic medicines as possible
x To promote generic competition by removing barriers to the market and by fostering more positive market conditions
Objectives
x Committed to working with the Department of Health and other stakeholders to continue exerting downward pressure on the NHS drugs bill whilst maintaining the sustainability of the industry
x Committed to providing high quality medicines to the NHS at affordable prices
x Believes that cost effective prescribing using generics should be the norm for the NHS: deviation form this should be based solely on clinical considerations
x Working to present products to patients in the most informative and supportive way
x Counter evergreening both generally and with respect to specific initiatives or product strategies undertaken by the originator
Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic…
Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug…
Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how…
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Recently appointed CEO of Health Innovation Manchester, Ben Bridgewater explains the organization’s goal of improving the lives of the people of Greater Manchester by ensuring a constant pipeline of innovation,…
Taking the conversation beyond Brexit, His Excellency Lars Thuesen, ambassador of Denmark to the UK, highlights the solid ties that have linked both countries since the Danes invaded the island…
The Ambassador of Switzerland to the UK, Alexandre Fasel, discloses what has been achieved so far with the ‘Mind the Gap’ strategy, aimed at safeguarding British-Swiss economic and business…
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back…
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short…
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and…
Liam O’Toole, CEO of Arthritis Research UK, discusses how arthritis impacts the British economy, raising public awareness of the condition, the potential ramifications of Brexit, and the importance of inter-stakeholder…
See our Cookie Privacy Policy Here
